|
|
|
| First Name: | William | | Last Name: | Messer | | Title: | Professor and Chair | | Advanced Degrees: | Ph.D. | | Affiliation: | The University of Toledo | | Department: | Pharmacology | | Street Address 1: | 2801 Bancroft St. | | City: | Toledo | | State/Province: | OH | | Zip/Postal Code: | 43606 | Country/Territory: | U.S.A. | | Phone: | 419-530-1958 | | Fax: | 419-530-1909 |
Disclosure:
(view policy)
|
Member reports the following financial or other potential conflicts of interest: [Last Modified: 15 November 2004]
I am a co-founder of Cognitive Pharmaceuticals Ltd, a company focused on developing treatments for neurological disorders including Alzheimer's disease and schizophrenia.
|
|
|
View all comments by William Messer
|
Animal Models, Chemistry/Pharmacology, Signal transduction, A-beta PP/A-beta, Neurobiology, Protein structure/chemistry, Tau/Cytoskeleton
|
Dr. Messer received his B.S. in biology from Springfield College in 1979. He did his graduate work in the Center for Brain Research at the University of Rochester, where he received an M.S. in Neuroscience in 1983 and a Ph.D. in Neuroscience in 1985. After completing his doctoral work, he joined the faculty at The University of Toledo in 1985 as Assistant Professor of Medicinal Chemistry. In 1990, Dr. Messer was the recipient of a five-year Research Career Development Award from the National Institutes of Health. He was awarded tenure and promoted to Associate Professor of Medicinal Chemistry in 1990 and to Professor of Medicinal Chemistry in 1995. He served as Interim Chair of Pharmacology for the 2000-2001 academic year before being named Professor and Chair of Pharmacology in 2001. |
Messer, W.S., Jr., M. Bohnett and J. Stibbe. Evidence for a preferential involvement of M1 muscarinic receptors in representational memory. Neurosci. Lett. 116: 184-189, 1990.
Messer, W.S., Jr., J.R. Stibbe and M. Bohnett. Involvement of the septohippocampal cholinergic system in representational memory. Brain Res. 564: 66-72, 1991.
Dunbar, P.G., G.J. Durant, Z. Fang, Y.F. Abuh, A. El-Assadi, D.O. Ngur, S. Periyasamy, W. Hoss, and W.S. Messer, Jr. Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4-oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists. J. Med. Chem. 36: 842-847, 1993.
Messer, W.S., Jr., Y.F. Abuh, Y. Liu, S. Periyasamy, D.O. Ngur, M.A.N. Edgar, A.A. El-Assadi, S. Sbeih, P.G. Dunbar, S. Roknich, T. Rho, Z. Fang, B. Ojo, H. Zhang, J.J. Huzl, III, and P.I. Nagy. Synthesis and biological characterization of 1,4,5,6-tetrahydropyrimidine and 2-amino-3,4,5,6-tetrahydropyrimidine derivatives as selective m1 agonists. J. Med. Chem. 40: 1230-1246, 1997.
Messer, W.S., Jr., Y.F. Abuh, K. Ryan, M.A. Shepherd, M. Schroeder, S. Abunada and A.A. El-Assadi. Tetrahydropyrimidine derivatives display functional selectivity for M1 muscarinic receptors in brain. Drug Dev. Res. 40: 171-174, 1997.
Huang, X.-P., S. Peseckis, F. Williams, and W.S. Messer, Jr. Pharmacological characterization of human m1 muscarinic acetylcholine receptors with double mutations at the junction of TM VI and the third extracellular domain. J. Pharmacol. Exp. Therap., 286(3): 1129-39, 1998.
Rajeswaran, W.G., Y. Cao, X.-P. Huang, M.E. Wroblewski, T. Colclough, S. Lee, F. Liu, P.I. Nagy, J. Ellis, B.A. Levine, K.H. Nocka and W.S. Messer, Jr. Design, synthesis and biological characterization of bivalent 1-methyl-1,2,5,6-tetrahydropyridyl-1,2,5-thiadiazole derivatives as selective muscarinic agonists. J. Med. Chem. 44(26): 4563-4576, 2001.
Messer, W.S., Jr., Cholinergic agonists and the treatment of Alzheimer’s disease. Curr. Top. Med. Chem. 2(4): 353-358, 2002.
Messer, W.S., Jr., K.A. Bachmann, C. Dockery, A.A. El-Assadi, E. Hassoun, N. Haupt, B. Tang and X. Li. Development of CDD-0102 as a selective M1 agonist for the treatment of Alzheimer’s disease. Drug Dev. Res. 57(4): 200-213, 2002.
Cao, Y., M. Zhang, C. Wu, S. Lee, M.E. Wroblewski, T. Whipple, P.I. Nagy, K. Takács-Novák, A. Balázs, S. Tőrös and William S. Messer, Jr. Synthesis and biological characterization of 1-methyl-1,2,5,6-tetrahydropyridyl-1,2,5-thiadiazole derivatives as muscarinic agonists for the treatment of neurological disorders. J. Med. Chem. 46: 4273-4286, 2003.
|
|
|
Home
